Trinity Biotech plc (TRIB)
| Market Cap | 7.87M -71.4% |
| Revenue (ttm) | 43.79M -28.9% |
| Net Income | -37.38M |
| EPS | -60.36 |
| Shares Out | 813.13K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,651 |
| Open | 9.83 |
| Previous Close | 9.75 |
| Day's Range | 9.30 - 9.83 |
| 52-Week Range | 7.94 - 52.50 |
| Beta | 0.99 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 16, 2026 |
About TRIB
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and o... [Read more]
Financial Performance
In 2025, Trinity Biotech's revenue was $43.79 million, a decrease of -28.87% compared to the previous year's $61.56 million. Losses were -$37.38 million, 17.6% more than in 2024.
Financial StatementsNews
Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress - PrePsia™ patent portfolio expands to nine granted U.S. and European patents - Company issues u...
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Trinity Biotech's Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure
- Collaboration with leading hyperscale data center company will support Trinovium's technical and commercial readiness through development of cooling technologies for next-generation AI and modular ...
Trinity Biotech secures $7M investment from Perceptive Advisors
Trinity Biotech (TRIB) announced it secured additional investment from funds managed by Perceptive Advisors, a life sciences investment firm and Trinity Biotech’s largest financial investor and primar...
Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
– Perceptive Advisors provides approximately $7.0 million of additional investment to further support strategic growth initiatives including CGM+, Trinovium and the Company's business transformation –...
Trinity Biotech trading halted, news pending
19:50 EDT Trinity Biotech (TRIB) trading halted, news pending
Trinity Biotech announces strategic collaboration agreement with Latch Medical
Trinity Biotech (TRIB) announced a strategic collaboration agreement with Latch Medical. The collaboration is intended to combine data streams from Trinity Biotech’s CGM+ wearable biosensor platform w...
Trinity Biotech announces plan to implement ADS ratio change
Trinity Biotech (TRIB) announced that it plans to change the ratio of the American depositary shares representing its Class A ordinary shares from one ADS representing 20 Class A ordinary…
Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
- Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develo...
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing ...
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech's CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows ...
Trinity Biotech's Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling
- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by 2033 1...
Trinity Biotech terminates standby equity purchase agreement with Yorkville
Trinity Biotech (TRIB) announced that it has formally provided notice of termination to YA II PN, an affiliate of financing partner Yorkville Advisors Global, in respect of its standby equity…
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressi...
Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market
- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-p...
Trinity Biotech Earnings release: Q1 2026
Trinity Biotech released its Q1 2026 earnings on June 18, 2026, summarizing the period's financial results.
Trinity Biotech Slides: Q1 2026
Trinity Biotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on June 18, 2026.
Trinity Biotech receives purchase orders for 2M units of TrinScreen HIV
Trinity Biotech (TRIB) announced that it has received additional purchase orders for over 2M units of its rapid HIV test, TrinScreen HIV. These orders are scheduled for fulfillment in Q3…
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on June 3, 2026, providing details about a securities offering with the SEC.
Trinity Biotech files to sell 167.95M American depositary shares
The 167.95M American depositary shares represent 3.36M ordinary shares.
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on May 13, 2026, providing details about a securities offering with the SEC.
Trinity Biotech Registration statement: Registration filing
Trinity Biotech filed a registration statement on May 13, 2026, providing details about a securities offering with the SEC.
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transfo...
Trinity Biotech Annual report: Q4 2025
Trinity Biotech has published its Q4 2025 annual report on April 30, 2026.